LHDXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LHDXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lucira Health's average Accounts Receivable for the three months ended in Sep. 2022 was $11.6 Mil. Lucira Health's Revenue for the three months ended in Sep. 2022 was $34.4 Mil. Hence, Lucira Health's Days Sales Outstanding for the three months ended in Sep. 2022 was 30.67.
The historical rank and industry rank for Lucira Health's Days Sales Outstanding or its related term are showing as below:
Lucira Health's Days Sales Outstanding declined from Sep. 2021 (46.60) to Sep. 2022 (30.67).
The historical data trend for Lucira Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucira Health Annual Data | |||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | |||||
Days Sales Outstanding | - | - | 397.57 | 54.01 |
Lucira Health Quarterly Data | ||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 46.60 | 29.22 | 33.34 | 83.03 | 30.67 |
For the Medical Devices subindustry, Lucira Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Lucira Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Lucira Health's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as
Days Sales Outstanding (A: Dec. 2021 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2020 ) | + | Accounts Receivable (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) | * | Days in Period |
= | ( (0.293 | + | 27.245) | / | 2 ) | / | 93.055 | * | 365 |
= | 13.769 | / | 93.055 | * | 365 | ||||
= | 54.01 |
Lucira Health's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:
Days Sales Outstanding (Q: Sep. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2022 ) | + | Accounts Receivable (A: Sep. 2022 )) | / | count ) | / | Revenue (A: Sep. 2022 ) | * | Days in Period |
= | ( (8.723 | + | 14.392) | / | 2 ) | / | 34.39 | * | 365 / 4 |
= | 11.5575 | / | 34.39 | * | 365 / 4 | ||||
= | 30.67 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucira Health (OTCPK:LHDXQ) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Lucira Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Anthony Joseph Allen | officer: Chief Operations Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Epq Llc, Lcovd Safe Ps | other: Less than 10% owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Chad Boeding | other: CEO of 10% owner | ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111 |
Epiq Capital Group, Llc | 10 percent owner | ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111 |
Epq Llc, Lcovd Ps | 10 percent owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Epq Llc, Lflu Ps | other: Less than 10% owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Epq Llc, Ltest Ps | other: Less than 10% Owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Richard Clavano Narido | officer: Interim CFO | 12 HANSEN CT, MORAGA CA 94556 |
Ghazi Kashmolah | officer: Ex. VP &Chief Quality Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Kevin Walter Collins | officer: Chief Revenue Officer | C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608 |
Dan George | officer: CFO and Treasurer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Erik T. Engelson | director, officer: President and Chief Executive | 1412 62ND STREET, EMERYVILLE CA 94608 |
Debkishore Mitra | director, officer: Chief Technology Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Tamanna Prashar | officer: Vice President | 1412 62ND STREET, EMERYVILLE CA 94608 |
Alison Mccauley | director | C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-08-2022
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 05-22-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
By Value_Insider Value_Insider • 11-17-2022
By sperokesalga sperokesalga • 02-22-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By GuruFocusNews GuruFocusNews • 05-09-2022
By Value_Insider Value_Insider • 11-01-2022
By PurpleRose PurpleRose • 08-23-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.